EGFR-tyrosine kinase inhibitors (TKIs) have demonstrated significant efficacy in eliciting tumor responses, particularly in NSCLC patients with EGFR mutations, surpassing traditional cytotoxic chemotherapy regimens. This evidence concerns the gene EGFR and neoplasm.